Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx Corp has demonstrated a strong financial position with a substantial balance sheet improvement after securing up to $60 million in committed capital through a new five-year credit facility, extending its debt maturity to 2031. In Q3, the company reported revenues of $21.5 million, representing a 5% year-over-year growth, with international sales expanding at a faster pace than the U.S. segment, while maintaining a robust gross margin of 75%. For the full year, Pulmonx achieved revenue of $90.5 million and a gross profit of $67.1 million, highlighting effective cost restructuring and improving profitability as key drivers for long-term growth potential.

Pulmonx Corp reported fourth quarter and full year 2025 financial results indicating a modest annual revenue growth of 8%, but the fourth quarter exhibited a decline to $22.6 million due to weaker performance in the U.S. market. The company also experienced a significant drop in cash, cash equivalents, and marketable securities, totaling $69.8 million at the end of 2025, which represents a decline of approximately $32 million year-over-year, alongside expected further cash depletion of around $23 million in 2026. Additionally, Pulmonx incurred operating expenses of $120.8 million for the year, culminating in a net loss of $54.0 million, further indicating operational challenges and a need for improved financial stability.